Agilent Technologies, Inc. (NYSE:A – Get Free Report) SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the sale, the senior vice president now owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Agilent Technologies Stock Up 2.1 %
NYSE:A opened at $147.41 on Thursday. The firm has a market capitalization of $43.20 billion, a price-to-earnings ratio of 35.10, a PEG ratio of 4.37 and a beta of 1.11. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average price is $137.60 and its 200 day moving average price is $126.13.
Agilent Technologies (NYSE:A – Get Free Report) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the firm posted $1.37 EPS. The business’s revenue was down 5.5% compared to the same quarter last year. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.51 earnings per share for the current fiscal year.
Agilent Technologies Announces Dividend
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on A shares. Wolfe Research started coverage on Agilent Technologies in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $140.00 price target on the stock. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 19th. Citigroup lifted their price objective on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price target on Agilent Technologies from $140.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Finally, UBS Group boosted their price target on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $138.29.
Get Our Latest Analysis on Agilent Technologies
Institutional Trading of Agilent Technologies
Several large investors have recently made changes to their positions in A. Nomura Holdings Inc. bought a new position in Agilent Technologies in the 4th quarter valued at $823,000. Livelsberger Financial Advisory bought a new position in Agilent Technologies during the fourth quarter worth about $26,000. PNC Financial Services Group Inc. lifted its holdings in Agilent Technologies by 2.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 172,458 shares of the medical research company’s stock worth $23,977,000 after acquiring an additional 4,627 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Agilent Technologies by 380.8% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 43,275 shares of the medical research company’s stock valued at $6,017,000 after purchasing an additional 34,275 shares during the period. Finally, Rovin Capital UT ADV raised its stake in shares of Agilent Technologies by 155.7% in the 4th quarter. Rovin Capital UT ADV now owns 4,785 shares of the medical research company’s stock valued at $665,000 after purchasing an additional 2,914 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
- Five stocks we like better than Agilent Technologies
- 3 Monster Growth Stocks to Buy Now
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- What is the Nikkei 225 index?
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.